UNSPSC 51313101: Cetirizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YO7261ME24, chemically known as acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- but generally known as cetirizine, which bears US NIH Compound Identifier 2678. European Medicines Agency schedules Cetirizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07451MIG.

UNSPSC 51313101 Cetirizine is a Commodity code that represents pharmaceutical products—specifically antihistamine medications—but the recent state and local opportunities tagged under this code diverge significantly from that nominal scope. The three most recent solicitations involve naloxone (an opioid overdose reversal agent), direct-to-manufacturer prescription fulfillment models, and multi-source generic pharmaceuticals with over-the-counter products, none of which are cetirizine or closely related antihistamines. State and local health departments, human services agencies, and cooperative purchasing alliances are the primary issuing bodies, with Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Department of Administration's Office of State Procurement appearing in the recent record. The code shows little relevant recent activity aligned with its cetirizine classification, suggesting either inconsistent code tagging by procurement offices or a shift in how the code is being applied in practice.

Geographic activity centers on Florida, Texas, and Minnesota based on the three recent opportunities. Seminole County, Florida posted an IFB (Solicitation IFB60459723LAS, due July 26, 2023 in the source, though posting date is listed as June 30, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription distribution models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with effective date July 1, 2026 and authorized distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson. Vendors responding to MMCAP must maintain $5 million commercial general liability coverage and comply with cGMP and Drug Supply Chain Security Act requirements. The code does not support pursuit activity directly aligned with cetirizine procurement.